SOURCE: Living Cell Technologies

May 12, 2008 00:50 ET

Living Cell Technologies Presents Unique Encapsulation Technology at International Conference

MELBOURNE, AUSTRALIA and AUCKLAND, NEW ZEALAND--(Marketwire - May 12, 2008) - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today announced that the Company has been invited to deliver a presentation on its unique encapsulation technology at the International Particles 2008 conference being held in Orlando, Florida, USA from May 10th -12th. The presentation is scheduled for US Eastern Time 9.45am May 12th.

Dr Anil Anal, Senior Scientist at LCT will speak about LCT's encapsulation technology that enables its lead product DiabeCell® to be implanted for the treatment of type 1 insulin dependent diabetes. The technology uses alginate derived from seaweed to encapsulate and protect pig insulin producing cells from rejection by the body's immune system. The alginate capsules have small nanoscale pores that allow nutrients to pass inwards for cells to survive long term and insulin to diffuse outwards.

Chief Executive Officer of LCT, Dr Paul Tan said, "LCT's encapsulation technology is a critical factor for the effectiveness of DiabeCell® which is presently in a Phase I/IIa diabetes clinical trial and showing very promising preliminary results as announced on 31st March. The invitation to present at Particles 2008 indicates that the importance and uniqueness of this method are now well recognized by leading scientists in the USA."

LCT has filed a patent on the selection of materials and method for placing cells in biocapsules.

Dr Anal, whose background is in the field of biocapsules and nanoparticles was also invited to chair a session on Encapsulation at the same conference on Sunday 11th May.

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of May 12 , 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.